Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 12/20 | 0.54 |
| ▸ | BACE1 | P56817 | 11/20 | 0.54 |
| ▸ | ACHE | P22303 | 10/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10025507 | 0.84 | BCHE (0.59) | BCHEBACE1ACHESLC6A2SLC6A4 | |
| SCHEMBL10059136 | 0.82 | BCHE (0.61) | BCHEBACE1ACHESLC6A2SLC6A4 | |
| SCHEMBL13541815 | 0.80 | BACE1 (0.61) | BCHEBACE1ACHESLC6A2SLC6A4 | |
| SCHEMBL9634965 | 0.78 | BCHE (0.66) | BCHEBACE1ACHE | |
| SCHEMBL34474307 | 0.77 | BCHE (0.59) | BCHEBACE1ACHE | |
| SCHEMBL11577003 | 0.77 | BCHE (0.69) | BCHEBACE1ACHESLC6A2SLC6A4 | |
| SCHEMBL10025523 | 0.77 | SLC6A2 (0.58) | BCHEBACE1ACHESLC6A2SLC6A4 | |
| SCHEMBL1310912 | 0.76 | ACHE (0.45) | ACHE | |
| SCHEMBL4830474 | 0.76 | BCHE (0.68) | BCHEBACE1ACHE | |
| SCHEMBL4830468 | 0.76 | BCHE (0.68) | BCHEBACE1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113397-A1 | Imidazo[1,2-a]pyridine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-1479681-A1 | IMIDAZO(1,2-a)PYRIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113397-A1 | Imidazo[1,2-a]pyridine derivative | MANBA, MAN2B1, ERG28 | BCHE 4686/4885BACE1 1125/4885ACHE 4021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.